Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26887000 | 0.81 | CTSD (0.41) | KDM4EPHF8KDM2ACTSDKDM5C | |
| SCHEMBL15285558 | 0.77 | KDM4E (0.48) | KDM4EPHF8KDM2ACTSDKDM5C | |
| SCHEMBL154159 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL3991034 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL9200108 | 0.75 | CTSD (0.44) | KDM4EPHF8KDM2ACTSDKDM5C | |
| SCHEMBL15055114 | 0.74 | PHF8 (0.46) | KDM4EPHF8KDM2AKDM5CNPC1 | |
| SCHEMBL3651890 | 0.72 | — | — | |
| SCHEMBL11831188 | 0.71 | — | — | |
| SCHEMBL4162171 | 0.71 | HDAC6 (0.33) | CTSD | |
| SCHEMBL1935269 | 0.71 | ALDH1A1 (0.39) | KDM4EALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013093931-A2 | NOVEL PRODRUGS OF PHENOLIC DRUGS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-06-27 | — | — | WO | claimed |
| WO-2023250157-A9 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023250157-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4185570-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| WO-2013093931-A2 | NOVEL PRODRUGS OF PHENOLIC DRUGS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2013-06-27 | — | — | WO | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202990-A1 | CYCLOHEXYL SUBSTITUTED TRIAZOLES | AVPR1A, AVPR1B, AVPR2 | KDM4E 2469/4885PHF8 4488/4885KDM2A 3833/4885 |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | KDM4E 2460/4885PHF8 779/4885KDM2A 2865/4885 |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | KDM4E 2806/4885PHF8 2578/4885KDM2A 2336/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | KDM4E 2968/4885PHF8 3226/4885KDM2A 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.